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Abstract
Purpose: To determine whether common DNA sequence variants within groups of genes encoding elements of stress-
activated mitogen-activated protein kinase (MAPK) signaling pathways are, in aggregate, associated with advanced AMD
(AAMD).
Methods: We used meta-regression and exact testing methods to identify AAMD-associated SNPs in 1177 people with
AAMD and 1024 AMD-free elderly peers from 3 large-scale genotyping projects on the molecular genetics of AMD. SNPs
spanning independent AAMD-associated genomic intervals were examined with a multi-locus-testing method (INRICH) for
enrichment within five sets of genes encoding constituents of stress-activated MAPK signaling cascades.
Results: Four-of-five pathway gene sets showed enrichment with AAMD-associated SNPs; findings persisted after
adjustment for multiple testing in two. Strongest enrichment signals (P=0.006) existed in a c-Jun N-terminal kinase (JNK)/
MAPK cascade (Science Signaling, STKE CMP_10827). In this pathway, seven independent AAMD-associated regions were
resident in 6 of 25 genes examined. These included sequence variants in: 1) three MAP kinase kinase kinases (MAP3K4,
MAP3K5, MAP3K9) that phosphorylate and activate the MAP kinase kinases MAP2K4 and MAP2K7 (molecules that
phosphorylate threonine and tyrosine residues within the activation loop of JNK); 2) a target of MAP2K7 (JNK3A1) that
activates complexes involved in transcriptional regulation of stress related genes influencing cell proliferation, apoptosis,
motility, metabolism and DNA repair; and 3) NR2C2, a transcription factor activated by JNK1A1 (a drugable molecule
influencing retinal cell viability in model systems). We also observed AAMD-related sequence variants resident in genes
encoding PPP3CA (a drugable molecule that inactivates MAP3K5), and two genes (TGFB2, TGFBR2) encoding factors
involved in MAPK sensing of growth factors/cytokines.
Conclusions: Linkage disequilibrium (LD)-independent genomic enrichment analysis yielded associations of AAMD with
aggregates of functionally related genes encoding constituents of the JNK MAPK signaling pathway. FDA-approved drugs
now exist to target constituents of stress-activated MAPK pathways and may offer reasonable approaches to preventing or
treating AAMD.
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Introduction
More than two million U.S. residents are living with advanced
age-related macular degeneration (AAMD) [1], the most common
cause of vision loss in people of western European ancestry. [2]
The worldwide cost of visual impairment attributable to AMD was
estimated at ,343 billion U.S. dollars ($255 billion in direct health
care costs) in a 2010 report by AMD Alliance International. [3]
The cardinal lesions of AAMD are proliferative growth of and
exudation from outer retinal vessels in the choriocapillaris (viz.
neovascular AMD) and neurodegeneration of the retinal pigment
epithelial (RPE) cell-photoreceptor complex (viz. geographic
atrophy).[4–6] AMD is a common complex disease and its
polygenic nature has been partially characterized from 19
strongly-associated (P#1610
28) loci in a multi-center study on
over 77,000 people. [7] Ward & Kellis [8] review works
demonstrating the influence of common alleles contributing small,
but meaningful effects in traits or disease risk [9] – as in the present
work, loci associated with complex traits at P-values far below
those considered significant on a genome-wide level have clustered
across the genome within DNA sequence encoding constituents of
biological pathways implicated in disease pathogenesis. [10] The
central premise here is that inference based on single loci may not
elucidate important contributions of genetic variants both
manifesting weak associations and the capacity to act together in
alteration of disease risk. [11,12].
PLOS ONE | www.plosone.org 1 August 2013 | Volume 8 | Issue 8 | e71239Findings from model systems investigating AMD-related path-
ophysiology [13–20] and our studies on the molecular genetics of
AMD [21,22] led us to examine the putative role of stress-
activated protein kinase (SAPK) signaling pathways in AMD
pathogenesis. Specifically, in vivo models of pathologic retinal
angiogenesis [23] and age-related macular degeneration [17] have
demonstrated that inhibition of c-Jun N-terminal kinase 1 (JNK1),
a SAPK, reduces: 1) retinal capillary dropout and neovascular
tufting in response to oxidative stress [14]; and 2) apoptosis,
vascular endothelial growth factor (VEGF, a key molecule driving
retinal angiogenesis) expression, and choroidal neovascularization
in response to laser-induced retinal damage. [17].
SAPK cascades contain MAPKs. MAPKs are evolutionarily
conserved kinases that act in phospho-relay systems to covalently
add phosphate to the side chain of either serine or threonine
residues within specific intracellular proteins – the effect of this
process is to alter enzymatic activity, catabolism, cellular
localization, and interaction of these phosphorylated proteins with
other molecules (e.g. protein kinases, phospholipases, transcription
factors, and cytoskeletal proteins). [24] MAPK protein phospha-
tases act to dephosphorylate serine and threonine residues on
MAPKs – causing a reversion of MAPKs to inactive states.
MAPKs operate in a number of signal transduction networks
responsible for cellular sensing and response during gene
expression, cell differentiation, movement, division, and death.
SAPKs characterize the JNK MAPK and p38 MAPK signaling
cascades – JNKs are environmental stress-, radiation-, and growth
factor-activated DNA binding proteins that increase activities of
the transcription complexes involved in cellular degeneration and
pathologic angiogenesis. [14] This body of in vivo evidence guided
our focus on stress-activated MAPK cascades.
We have previously reported single locus associations for
AAMD with DNA sequence variants resident in genes encoding
constituents of MAPK pathways. [21,22] AAMD-associated single
nucleotide polymorphisms (SNPs) also exist in genes encoding cell
surface and nuclear receptors known to act in MAPK pathways –
such genes include the members of the: 1) peroxisome proliferator
activator receptor (PPAR)/retinoid X receptor (RXR) complex
[22]; 2) VEGF signaling system[22,25–27]; and, 3) insulin
signaling system. [28].
The primary aim of the present study was to determine whether
DNA sequence variants in genes encoding constituents of JNK
MAPK and p38 MAPK pathways were associated with AAMD.
We reasoned that MAPKs and MAPK protein phosphatases of
these pathways, their targeting enzymes, ligands, targets, and
metabolites may form systems that influence AMD pathogenesis
through regulation of aggregate transcriptional responses to chronic
environmental and biochemical cellular stressors to which the
retina is commonly exposed (these include hypoxia, ultraviolet
light, inflammatory cytokines [29] and stimuli influencing barrier
function [30]).
We applied findings from a genome-wide association project
(NEI-AMD, the NEI Study of Age-Related Macular Degenera-
tion) to a pathway-based genome-wide analytic method (INRICH)
[11] to test for enriched association signals in five published sets of
genes encoding MAPK pathway constituents including SAPKs
(see Methods section and Table 1). In this process we examined
linkage disequilibrium (LD)-independent genomic intervals to
determine whether common DNA sequence variants within
groups of genes encoding constituents of MAPK pathways were,
in aggregate, more strongly associated with AAMD than expected
by chance alone. This multi-locus method uses positional
clustering of SNPs to account for various genomic confounding
factors (such as varying gene size, SNP density, LD, and local
clustering of functionally related genes) that may otherwise
produce spurious increases in the magnitude of association
measures favoring risk (the result of which would inflate the false
positive rate [31]). AAMD-associated LD-independent genomic
intervals containing 1-or-more AAMD-related SNPs were defined
from the positional coordinates of sequence variants attaining P-
values #0.002 in meta-analysis on AAMD endpoints from NEI-
AMD. NEI-AMD data were from three independent and
geographically distinct U.S.-based cohorts of western European
ancestry participating in large-scale projects designed to investigate
the molecular genetics of AMD (details on study cohorts exist at
the National Center for Biotechnology Information, http://www.
ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.
cgi?study_id=phs000182.v2.p1). The P-value threshold of 0.002
for pathway analysis was chosen as it retains about 5% of AAMD-
associated genomic loci occurring in genomic regions. We
analyzed a total of 1177 people with AAMD and 1024 of their
AMD-free peers, aged 65 years-or-older at time of genotyping.
SNPs.
We now report linkage disequilibrium-independent genomic
enrichment associations of AAMD with aggregates of function-
ally related genes encoding constituents of stress-activated
MAPK signaling pathways. Analysis of AAMD-associated JNK
MAPK gene set constituents for co-inheritance with previously
identified genome-wide AMD-associated (P#1.0610
28) loci
showed null findings (incomplete linkage disequilibrium with r
2
values ,0.20). As multiple drug targets exist in SAPK-resident
systems, these may offer reasonable options for preventing or
treating AAMD.
Methods
Data used for genetic analyses in this report were obtained from
the NEI-AMD Database at the U.S. National Center for
Biotechnology Information (NCBI) database of Genotypes and
Phenotypes (dbGaP). Details on NEI-AMD exist at http://www.
ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.
cgi?study_id=phs000182.v2.p1 (Accessed 2013 July 9). NEI-
AMD is a collaborative of researchers from the University of
Michigan, Mayo Clinic, University of Pennsylvania, and the Age-
Related Eye Disease Study (AREDS) group. NEI-AMD research-
ers collected clinical data and DNA from people affected with
AMD and their elderly AMD-free peers. The NEI was the
primary sponsor of this effort. Institutional review boards at each
NEI-AMD study site reviewed and approved the study protocols.
Each participant provided written informed consent in accordance
with the Declaration of Helsinki.
Subjects and Study Design
Details on the NEI-AMD genome-wide association (GWA)
study exist at the link in the first paragraph of this section. In
brief, three independent cohorts from the University of
Michigan in Ann Arbor, the University of Pennsylvania in
Philadelphia, and the Mayo Clinic in Rochester, Minnesota
contributed data to this genome-wide association study. Our
analytic sample contained respectively 675, 227, and 275 people
with advanced AMD from the University of Michigan,
University of Pennsylvania, and The Mayo Clinic. There were
512, 198, and 314 AMD-free people, aged $65 years in these
respective sites. We restricted the AMD-free comparison cohort
to people $65 years-of-age. The purpose of selecting our oldest
AMD-free participants was to reduce the chances of including
false negatives in analyses.
MAPK Pathways and AMD
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People with AAMD had GA and/or NV AMD. Experienced
graders (ophthalmologists) classified outcomes according to AMD
diagnosis in the worse eye. Our AMD-free comparison group had
no large or intermediate drusen in either eye, with no more than 5
hard drusen or small drusen and pigment changes in one eye only.
If small drusen or pigment changes were present in the AMD-free
group, they were neither bilateral nor extensive. All participants
received examinations and gradings by the study ophthalmologists.
No participant exhibited history or evidence of: 1) retinal insult
rendering the fundus ungradable; 2) severe macular disease or
vision loss onset prior to 40-years-of-age; or 3) diagnosis of juvenile
macular or retinal degeneration, macular damage resulting from
ocular trauma, retinal detachment, high myopia, chorioretinal
infection, or inflammatory disease, or choroidal dystrophy.
Genotyping
All specimens were genotyped with DNA microarrays at the
Johns Hopkins University Center for Inherited Disease Research
(CIDR, Baltimore, MD, USA) using the ILLUMINA Hu-
manCNV370v1 chip. This chip was selected by the NEI Study
of Age-Related Macular Degeneration researchers (see link above).
The HumanCNV370v1 permits tests on 370,404 DNA sequence
variants. The feature set may be accessed on the dbSNP short
variations database located at: (http://www.ncbi.nlm.nih.gov/
SNP/snp_viewBatch.cgi?sbid=1047132).
Statistical Analyses
All sequence variants analyzed for AAMD relationships passed
process quality and analytic filters for missingness (,5%), minor
allele frequency (.1%), and Hardy-Weinberg equilibrium (HWE
P#1610
26 in the AMD-free group). We used PLINK (version
1.07, http://pngu.mgh.harvard.edu/purcell/plink/) [32] and SAS
(version 9.1, Cary, NC) software for these purposes.
We first examined the allelic distributions of SNPs in people
with AMD (relative to the AMD-free comparison group) using
age-, sex-, and smoking-adjusted logistic regression analyses.
Combined estimates of association were computed using PLINK
with meta-analytic techniques under constraints of sample
heterogeneity (using Cochrane’s Q for evaluation). P-values and
odds ratios were chosen from random effects models in instances
when significant heterogeneity was demonstrated.
We then used INRICH [11] to examine statistical enrichment
of five MAPK pathway gene sets. The five SAPK-containing gene
sets were curated by experts in the MAPK signaling field; these
were: 1) a general MAPK gene set including constituents of the 4
major MAPK cascades (JNK MAPK, p38 MAPK, ERK1/ERK2,
ERK5– containing 86 genes with 49 present on our chip)
published at BioCarta (http://www.biocarta.com); 2) a general
MAPK gene set (261 genes, 144 present on our chip) published at
the Kyoto Encyclopedia of Genes and Genomes pathway maps
database (http://www.genome.jp/kegg); 3) a p38 MAPK gene set
(35 genes, 23 present on our chip) published by the AAAS Science
Signaling Signal Transduction Knowledge Environment (http://
stke.sciencemag.org/cm); 4) a p38 MAPK gene set (35 genes, 23
present on our chip) published by BioCarta (39 genes, 21 present
on our chip); and, 5) a JNK MAP gene set (38 genes, 25
represented on our chip) published by the AAAS Science Signaling
Signal Transduction Knowledge Environment. We examined the
general sets to determine whether shared or distinct patterns of
association clustered between or within specific MAPK cascades.
AMD-associated LD-independent genomic intervals were com-
puted using tag SNP selection tools in PLINK (r
2=0.50,
associated SNPs #1000 kb of tag SNP) on variants attaining
statistical significance for AMD relationships at P#0.002. This
significance threshold was chosen following to previous work [33]
that retains the top 5% of genic intervals in the single-variant
association tests. We applied 100,000 permutations in our first
phase of INRICH enrichment analysis and 10,000 in the bootstrap
replication phase for correction of multiple testing.
Functional Annotation of AAMD-associated MAPK Genes
Information on functional annotation and regulatory features
was obtained from HaploReg (www.broadinstitute.org/
mammals/haploreg/).
Results
MAPK Pathway Enrichment
Table S1 contains demographic characteristics of our analytic
groups. There were 21 genes from the 5 tested MAPK pathway
gene sets containing at least one AAMD-associated interval
significant at P#0.002. AAMD-associated genomic regions were
significantly enriched for genes encoding constituents of four-of-
five MAPK pathway gene sets (Table 1).
Table 1. Five published MAPK pathways examined for enrichment with AAMD-associated genomic intervals.
Genes Enrichment P-value
Pathway Source In Pathway Tested AMD-Associated Empirical Adjusted
MAPK* BioCarta
a 86 49 9 0.014 0.037
MAPK* KEGG
b 261 144 19 0.153 0.339
JNK MAPK STKE
c 38 25 6 0.002 0.006
p38 MAPK STKE 35 23 5 0.021 0.057
p38 MAPK BioCarta 39 21 5 0.023 0.070
Note: AAMD, advanced age-related macular degeneration;
ainformation on BioCarta pathways exists at: http://www.biocarta.com;
binformation on KEGG pathways exists at: http://www.genome.jp/kegg/pathway (MAPK: hsa04010);
cinformation on STKE pathways exists at: http://stke.sciencemag.org (JNK MAPK: CMP_10827; p38 MAPK: CMP_10958).
*‘MAPK’ pathways from BioCarta and KEGG include constituents of the 4 major MAPK cascades (JNK MAPK, p38 MAPK, ERK1/ERK2, ERK5). Empirical P-values for pathway
interval enrichment were obtained from permutation test applying 100,000 iterations. Enrichment P-values were adjusted for multiple testing, as described in the
Methods section.
doi:10.1371/journal.pone.0071239.t001
MAPK Pathways and AMD
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testing. Strongest enrichment signals existed for constituents of the
JNK MAPK pathway of 38 genes published in the AAAS Science
Signaling Signal Transduction Knowledge Environment (STKE,
http://stke.sciencemag.org/cgi/cm/stkecm;CMP_10827 ). In this
gene set, 7 LD-independent AAMD-associated genomic regions
existed in 6 genes of 25 tested. The enrichment of the JNK MAPK
pathway set was consistently observed when potential regulatory
regions (i.e. 20–50 kb up/downstream of transcription starting/
ending sites of reference genes) were included as genic regions
(adjusted enrichment P-value=0.0062). Both the STKE and
BioCarta p38 MAPK pathway gene sets showed marginal
significance after accounting for the number of statistical tests
performed (the respective adjusted enrichment P-values are 0.057
and 0.070).
Figure 1 highlights findings on regulators and targets of
AAMD-associated constituents within the STKE JNK MAPK
Pathway. Table 2 contains findings for specific SNPs tagging the
AAMD-associated intervals in the JNK MAPK pathway set. Most
associations showed ,30% difference in the likelihood of having
AAMD associated with the respective MAPK-related sequence
variants, after adjusting for age-, sex-, and smoking. Table 3
contains annotations of all SNPs significant in our analyses. For
the STKE JNK MAPK pathway genes, SNPs were present in
highly conserved regulatory elements in: 1) three MAP kinase
kinase kinases (MAP3K4, rs1488, P#6.47610
24 and rs3798917,
P#6.87610
24 | MAP3K5, rs1011969, P#2.15610
23 | MAP3K9,
rs10483834, P#1.90610
23) that phosphorylate and activate the
MAP kinase kinases MAP2K4 and MAP2K7– these MAP2Ks
phosphorylate key threonine and tyrosine residues within the
activation loop of JNK; 2) a target of MAP2K7 (JNK3A1,
rs9307016, P#2.02610
23) that activates complexes involved in
transcriptional regulation of stress related genes influencing cell
proliferation, apoptosis, motility, metabolism and DNA repair;
and 3) a transcription factor activated by JNK1A1 (NR2C2,
rs1344825, P#2.05610
23) – JNK1A1 (untested in our study) is a
drugable DNA binding protein demonstrated to influence retinal
vascular cell viability in in vivo model systems. [14,17] AAMD-
related sequence variants were also resident in genes encoding
PPP3CA (PPP3CA, rs2732514, P#5.57610
23) – a drugable
molecule that inactivates MAP3K5– and at least two genes
(TGFB2, rs2796813, #1.60610
23; TGFBR2, rs1155708,
P#3.06610
23) encoding factors involved in JNK MAPK sensing
of growth factors/cytokines. Figure S1 contains information on
the location of AAMD-associated genes within the full STKE JNK
MAPK Pathway. Table S4 shows representation of AMD-
associated genes by each of the five MAPK gene sets containing
SAPKs.
Potential Influence of Other AMD-associated SNPs on
MAPK Findings. Approximately 20 loci strongly associated
with AMD (P-values #1610
28) were recently reported in a multi-
center study on over 77,000 people [7]. Our findings were
concordant for a number of these regions – Table S2 contains a
list of AMD-related SNPs statistically significant in our cohort at
P#1.0610
28 in age-, sex, and smoking-adjusted models. Condi-
tioning our single locus analyses on the two variants with strongest
associations (rs932275, HTRA1, P#3.5610
248; rs1329428 CFH,
P#3.3610
255) attenuated the magnitude of relationships in our
MAPK-related SNPs in Table 2; however, all sequence variants
discussed in the MAPK Pathway Enrichment section (directly above)
remained significant at P#0.05. To examine potential coinheri-
tance of SNPs in Table S2 with AMD-associated SNPs of the JNK
MAPK AAMD-associated intervals in Table 2, we computed
measures of linkage disequilibrium. In no case was the r
2 value of a
SNP in Table S2 with a SNP in Table 2 greater than 0.2. Our
conclusion is that findings for the MAPK-pathway-resident SNPs
are biologically plausible and concordant with those in the model
systems.
AAMD-associated SNPs in Genes Encoding Factors
Driving JNK MAPK Sensing and Response
Via receptor tyrosine kinases (RTKs), cytokine receptors, AND
guanine nucleotide (G)-protein coupled receptors (GPCRs) JNK
MAPK cascade constituents sense and respond to hypoxia,
radiation, survival and growth factors, cytokines, chemokines,
hormones, and amino acid neurotransmitters. We extended our
examination of the JNK MAPK cascade components to include
DNA variants in SAPK system genes encoding ligands, receptors,
and molecules embedded in, or associated with the plasma
membrane dynamics.
Survival Factors. Cell survival factors activate SAPK-driven
signal transduction pathways via RTKs. VEGF is a key pro-
angiogenic factor in vasoproliferative retinopathies in its capacity
to induce endothelial cell migration and proliferation, microvas-
cular permeability, endothelial cell release of metalloproteinases
and interstitial collagenases, and endothelial cell tube forma-
tion.[34–36] VEGF activates MAPKs via insulin-like growth factor
1 (IGF1) and recent work on primary human RPE (hRPE) cells
has demonstrated that constituents of MAPK pathways are likely
to influence IGF1-mediated retinal angiogenesis. [15] We
observed AAMD associations with a number of SNPs in insulin
signaling system genes. Most notable was a missense variant in
insulin-like growth factor-binding protein 1 (IGFBP1, Ile253Met,
rs4619, P#0.003) that yields an amino acid substitution proximal
to a cell attachment site in the mature protein (NCBI Reference
Sequence: NP_000587.1). We also observed relationships of AMD
with a highly conserved 39 UTR-resident SNP in IGF1 (rs6219,
P#0.015) and a highly conserved intronic variant overlapping
histone promoter marks in insulin-like growth factor-binding
protein 5 (IGFBP5, rs3770472, P#0.006).
Growth Factors. Growth factors activate SAPK-driven
signal transduction pathways via RTKs. We have discussed our
findings for TGBFB2 and TGFBR2, above. Activation of the JNK
MAPK cascade by growth factors leads, through the small
GTPase Ras, to the activation of 1-phosphatidylinositol 3-kinase
(PI3K) complexes. We observed AAMD-associated sequence
variants in genes encoding regulatory subunit 4 phosphatidylino-
sitol 3-kinase (PIK3R4, rs11713445, P#1.37610
24 | rs2200368,
P#2.11610
24) and the 39 untranslated region (UTR) of regula-
tory subunit 6 phosphatidylinositol 3-kinase (PIK3R6, rs2242375,
P#1.81610
23). Growth factor-induced JNK MAPK cascade
activation may also proceed post-binding at the RTK via an
interaction of growth factor receptor bound protein 2 (GRB2) with
GRB2-associated binding protein 1 (GAB1). We observed an
AAMD-associated SNP in GAB1 (rs3805236, P#1.01610
23).
Chemokines, Hormones, Amino Acid
Transmitters. Chemokines, hormones, and amino acid trans-
mitters activate SAPK-driven signal transduction pathways via
GPCRs. After ligands bind GPCRs at the plasma membrane, G-
protein beta and gamma binding proteins are activated and
increase activation of phosphatidylinositol 3-kinase gamma in a
cascade subsequently involving Rac and MAP3K9. We observed
AAMD-associated variants in an intronic area with histone
promoter marks in G-protein beta polypeptide 3 (GNB3,
rs4334421, P#2.20610
23) and a highly conserved missense
variant in G-protein gamma 7 (GNG7, rs5442, Gly272Ser,
P#1.03610
23) that yields a residue change within an evolution-
arily conserved aspartate-tryptophan repeat sequence (WD 1)
MAPK Pathways and AMD
PLOS ONE | www.plosone.org 4 August 2013 | Volume 8 | Issue 8 | e71239Figure 1. AAMD-associated genes enriching STKE JNK MAPK pathway. Diagram was generated with Ingenuity Pathway AnalysisH software
and is based on Johnson GL, Lapadat R, JNK Pathway, Science’s STKE, CMP_10827. Unshaded (white) symbols represent genes that were not tested.
Symbols shaded in gray represent relationships with P-values .0.002. Symbols shaded in red represent relationships significant at P-values #0.002.
Full names for symbols representing genes exist at www.ncbi.nlm.nih.gov/gene/. Values beneath symbols are P-values for association computed with
meta-analysis on of age-, sex, and smoking-adjusted odds ratios from 3 independent cohorts participating in large-scale genotyping projects on the
molecular genetics of AMD (1177 people with AAMD and 1024 of their AMD-free peers).
doi:10.1371/journal.pone.0071239.g001
Table 2. AAMD-associated sequence variants (P#0.005)* resident in genes of the STKE JNK MAPK pathway.
SNP Feature OR (95%CI)
Symbol SNP Ref. Alleles Cohort 1 Cohort 2 Cohort 3 ORmeta Pmeta
GAB1 rs3805236 T|C 0.68(0.53,0.87) 0.68(0.46,1.00) 0.94(0.66,1.32) 0.74 1.01610
23
MAP3K4 rs1488 G|A 1.48(1.16,1.90) 1.58(1.07,2.36) 1.04(0.72,1.49) 1.37 6.47610
24
rs3798917 G|T 1.45(1.10,1.90) 1.29(0.84,1.98) 1.44(0.97,2.12) 1.41 6.87610
24
MAP3K5 rs1011969 A|C 1.30(1.00,1.70) 1.01(0.65,1.57) 1.97(1.31,2.94) 1.37 2.15610
23
rs9402839 A|G 0.72(0.54,0.95) 0.72(0.46,1.14) 0.78(0.51,1.22) 0.73 4.29610
23
MAP3K9 rs10483834 G|A 0.80(0.63,1.03) 0.69(0.47,1.03) 0.69(0.48,0.99) 0.75 1.90610
23
JNK3A1 rs9307016 C|T 0.76(0.59,0.99) 0.72(0.47,1.09) 0.69(0.46,1.03) 0.74 2.02610
23
rs7440491 C|A 0.77(0.60,0.98) 0.84(0.57,1,25) 0.71(0.49,1.04) 0.77 4.81610
23
rs1469869 T|C 1.29(0.99,1.62) 1.46(0.96,2.20) 1.35(0.91,1.99) 1.34 3.02610
23
NR2C2 rs1344825 C|T 0.84(0.66,1.06) 0.54(0.35,0.83) 0.74(0.52,1.09) 0.75 2.05610
23
Note: Odds ratios (ORs) and 95% confidence intervals (95% CIs) were computed, respectively, in Cohort 1/2/3 with age-, sex-, and smoking-adjusted logistic regression
models comparing 675/227/275 people with advanced AMD (AAMD) to 512/198/314 of their AMD-free peers, aged .65 years at the time of genotyping. Participants
from Cohort 1 were examined at the University of Michigan Ann Arbor. Those in Cohort 2 were examined at the University of Pennsylvania in Philadelphia. Those in
Cohort 3 were examined at the Mayo Clinic in Rochester, Minnesota. Alleles are listed as minor|major.
*Only SNPs significant at P#0.002 were considered as AAMD-related in the pathway analysis. In most cases dominant models of inheritance (grouping minor allele
homozygotes with heterozygotes) yielded strongest relationships – ORs reported here are from analyses using this model, with the exception of that for NR2C2 (here
the additive model was used). Table S3 contains allelic frequencies of variants in this table.
doi:10.1371/journal.pone.0071239.t002
MAPK Pathways and AMD
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protein.
Discussion
Using data from a whole genome genotyping microarray and a
multi-locus enrichment analysis [11], we have identified AAMD-
associated regions related to a ,30% change in the likelihood of
having AAMD within 6-of-25 tested constituents of the stress-
activated protein JNK MAPK signaling cascade (a pathway
involved in cellular sensing and response during gene expression,
cell differentiation, movement, division, and death); AAMD-
associated SNPs resident in MAPK pathway genes were not co-
inherited with previously identified high risk loci. In addition to
identifying AAMD-associated factors that may act in aggregate
response to stress from processes implicated in AMD pathogenesis,
we now report on a number of AAMD-associated factors involved
as constituents of sensing modules essential to MAPK response
complex activation.
While the magnitude of relationships from our pathway-based
analyses was less than those conventionally reported for single
locus tests of genome wide significance, our findings offer
interpretation with strong biological plausibility. JNK and p38
mitogen activated protein kinases (MAPKs) have been linked in a
cell system to mRNA stability of VEGF. Page `s et al. used a
Chinese hamster lung fibroblast line (CCL39) to demonstrate that
non-specific pharmacologic activation of JNKs altered post-
transcriptional regulation of VEGF by increasing VEGF mRNA
stabilization. [13] The same team reported that VEGF mRNA
induction is inhibited by JNK blockade with the drug SB202190.
Guma et al. [14] used an in vivo murine model of pathologic retinal
Table 3. Annotations of AAMD-associated sequence variants resident in MAPK pathways.
SNP Feature
Symbol
Pathway SNP Reference Location Regulatory Element Conserved
AKT3
a rs12031994 Intron Enhancer*, DNase* No
CACNA1A
a rs4926242 Intron No
CREB5
d rs10233653 Intron Enhancer*, DNase No
rs160342 Intron – No
rs160343 Intron DNase* Yes*
rs41276 Intron – Yes
FGF14
a rs2984842 Intron – No
GAB1
c rs3805236 Intron – No
MAP2K2
a,b rs350818 39 UTR* DNase No
MAP3K4
a,b,c rs1488 39UTR – Yes
rs3798917 Intron ENH* Yes*
MAP3K5
a,b,c,d,e rs1011969 Int., SYN* ENH, DNase* Yes*
MAP3K9
b,c,e rs10483834 Intron PRO*, ENH*, DNase* Yes*
JNK3A1
a,b,c rs9307016 Intron DNase* Yes*
MAPK8IP2
a rs2238834 Intron PRO, DNase No
MAPKAPK2
a,e rs4256810 Intron Enhancer, DNase Yes*
NFATC2
a rs2273642 Intron DNase* No
NR2C2
c rs1344825 Int., 59UTR* PRO*, ENH*, DNase No
PLA2G12A
a rs2285714 SYN, 59UTR* PRO*, DNase Yes
PLA2G4A
a rs7519192 Intron ENH*, DNase (RPE) Yes*
PPP3CA
a rs3804357 Intron – No
RPS6KA2
a,b rs2072641 Intron DNase No
TAOK3
a rs514826 Int., 39UTR* PRO, DNase No
rs571113 Intron PRO, ENH, DNase* No
TGFB2
a,b,e rs2796813 Intron PRO*, ENH*, DNase Yes*
TGFBR2
a rs1155708 Intron PRO*, ENH*, DNase* Yes*
Note: DNase, DNase hypersensitivity cluster; ENH, histone enhancer mark; Int., variant resident in intron; JNK, genes present in STKE JNK MAPK Pathway (see Tables 1
and S4); PRO, histone promoter mark; RPE, retinal pigment epithelial cell; SNP, single nucleotide polymorphism; SYN, synonymous coding variant; UTR, untranslated
region.
*Annotations marked with an asterisk are for qualities of sequence variants in nearly complete linkage disequilibrium (r
2$0.80) with the AAMD-associated variant in the
SNP column. Full names of genes represented by gene symbols exist at http://www.ncbi.nlm.nih.gov/gene. Information on regulatory features was obtained from
HaploReg (www.broadinstitute.org/mammals/haploreg/). Pathway:
aKEGG MAPK Signaling Pathway;
bBioCarta MAPK Signaling Pathway;
cSTKE JNK MAPK Pathway;
dSTKE p38 MAPK;
eBioCarta p38 MAPK Pathway.
doi:10.1371/journal.pone.0071239.t003
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hypoxia-induced retinal VEGF production; this team provided the
first evidence that genetic JNK1 deficiency (JNK1
2/2 mouse) and
pharmacologic JNK1 inhibition (D-JNKi) ameliorates retinal
capillary dropout and neovascular tufting in response to oxidative
stress. Du et al. used a murine model of neovascular AMD to
demonstrate that JNK1 deficiency or JNK inhibition leads to a
decrease in apoptosis, VEGF expression, and reduction of
choroidal neovascularization. The choroid is the primary vascular
bed damaged in AMD. [17] A number of model cell systems in
immortalized RPE cells have implicated constituents of the JNK
MAPK pathway in retinal cell survival.
The BioCartaH MAPK Pathway gene set (http://www.biocarta.
com) also showed significant enrichment of AMD-associated genes
(adjusted P-value=0.037). This pathway gene set contains
constituents of the SAPK cascades (JNK MAPK and p38 MAPK),
the extra-cellular-regulated kinases (ERK1 and ERK2, mitogen-
activated MAPKs), and the ERK5 cascade (a system of stress- and
mitogen-activated extra-cellular-regulated kinases). Although there
was no clear evidence in the enrichment of AAMD-associated
genes within a specific constituent, we see a reasonable basis to
examine mitogen-activated (ERK1/ERK2) cascades in future
studies. As discussed above, VEGF activates MAPKs via insulin-
like growth factor (IGF1). PD98059, a selective inhibitor of MAPK
kinases ERK1 and ERK2, suppressed IGF1-induced hRPE cell
proliferation and inhibited IGF1-induced VEGF synthesis. [15]
Anathrax lethal toxin (LeTx) has a similar activity profile to
PD98059 in cancer cell lines [37] and is known to inactivate
MAPK signaling pathways by cleaving the amino termini of
MAP2K1, MAP2K2, MAP2K3, MAP2K4, MAP2K6, and
MAP2K7 (reviewed in ref [16]). Bromberg-White et al. [16] used
an in vivo murine model of retinal vascular development to
examine the effects LeTx on nascent retinal vascular networks.
Injecting LeTx during a critical developmental phase character-
ized by the presence of active MAPK in sprouting (nascent) retinal
capillaries led to abrogation of branching morphogenesis in the
inner retinal plexus. Four days post-injection, florid focal retinal
neovascular growth occurred in the outer retina; this pathologic
condition was linked to elevated vitreal VEGF concentrations.
Our inferences were constrained by the coverage of sequence
variation on the genotyping platform, natural history (late-onset
presentation) of AMD, and a priori-selection of a significance
threshold. It is important to acknowledge that our data on
genotypes are from a convenience sample of loci available on the
commercial (viz. non-customized) 300 K micro-arrays we used.
The power of this study is thus limited by the sparse coverage of
the genotyping chip. In no instance did we have data on all genes
in a pathway – and the data available were not collected with the
intention of examining specific protein coding regions or areas
overlapping active regulatory sites. Regarding the AMD endpoint:
because the likelihood of having AMD increases 2-to-6 fold after
age 75, we conducted careful selection of an appropriate elderly
AMD-free comparison group ($65-years-of-age) that was chosen
to reduce the likelihood of misclassifying people in subclinical
phases of AMD as controls. Lastly, overrepresentation-based
enrichment methods, such as INRICH [11] require a pre-specified
P-value threshold to define a list of significant SNP/gene/intervals
as input. Clearly, this nominal P-value threshold is critical in
determining the power of the study, however, the optimal value
would largely depend on the proportion of truly trait-associated
GWAS signals vs. false-positive ones, which is unknown a-priori
and specific to each phenotype [38]. As such, although we
confirmed a significant enrichment of pathway genes using the
`pathway enrichment global p-value Gp’ output (Gp,0.006) [11]
using the top 5% of association signals, we could have missed
stronger enrichment of the MAPK pathway genes tested under
different P-value thresholds.
In summary, we have provided novel findings on the
relationship of MAPK pathway constituents with AAMD.
Common DNA sequence variants within groups of genes encoding
both response and sensing constituents of these pathways were, in
aggregate, more strongly associated with AAMD than expected by
chance alone. FDA-approved drugs now exist to target constitu-
ents of these pathways and may offer reasonable approaches to
preventing or treating AAMD.
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